The Era Of Billion Dollar Pharma Settlements
Executive Summary
Abbott Laboratories is the third pharmaceutical company to reach a settlement with the Department of Justice in excess of $1 billion. A look at the deals struck since Eli Lilly began the billion dollar club in 2009 shows the activities the government is investigating and the level of liability that companies face.
You may also be interested in...
Decade In Review: Biopharma's Shifting Legal Landscape
Emergence of the inter partes review process dramatically changed the patent dispute arena. The decade also brought biosimilar litigation, generic price-fixing complaints, opioid lawsuits and new government investigations and antitrust actions.
DOJ Casting Wider Net In Pharma Kickback Probes
Government is pursuing behavior it once would have taken a pass on, former DOJ attorney notes; pharma companies have inked 16 settlements in past year.
DOJ's Investigation Of Reckitt's Suboxone Promotions Marks The Return Of The Big Settlement
$1.4b payment to settle investigation of marketing of opioid addition treatment is biggest for a pharma in several years.